SHAREHOLDER ALERT: Monteverde and Associates PC Announces an Investigation of Pandion Therapeutics, Inc. - PAND
Tags:
NEW YORK, Feb. 27, 2021 /PRNewswire/ --
Juan Monteverde, founder and managing partner at Monteverde and Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Pandion Therapeutics, Inc. ("PAND" or the "Company") (PAND) relating to its proposed acquisition by Merck. Under the terms of the agreement, PAND shareholders will receive $60.00 in cash per share.
The investigation focuses on whether Pandion Therapeutics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.
Click here for more information: http://monteverdelaw.com/case/pandion-therapeutics-inc. It is free and there is no cost or obligation to you.
About Monteverde and Associates PC
We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers and Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers and acquisitions class action cases.
If you own common stock in Pandion Therapeutics, Inc. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.
Contact:Juan E. Monteverde, Esq.MONTEVERDE and ASSOCIATES PCThe Empire State Building350 Fifth Ave. Suite 4405New York, NY 10118United States of America[email protected]Tel: (212) 971-1341
Attorney Advertising. (C) 2021 Monteverde and Associates PC. The law firm responsible for this advertisement is Monteverde and Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
SOURCE Monteverde and Associates PC
http://www.monteverdelaw.com
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM - 9 PM ET
